Based on this, pembrolizumab was the first immunotherapy to receive accelerated approval from the United States Food and Drug Administration in 2018 as a second-line treatment for patients with metastatic cervical cancer with positive PD-L1 expression. This evidence concerns the gene CD274 and cervical cancer.